ClinicalTrials.gg
CompletedNCT04048135Updated Apr 2, 2024Results posted

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

A Phase 1/2 interventional study of Pegozafermin and Placebo in NASH, sponsored by 89bio, Inc.. Completed at 26 sites in 2 countries. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by 89bio, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
162nd of 460
101 · median 56
Started
2019
with 61 others
Phase 1/2
14 of 547
1 open now
Registered
303rd of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 162nd largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 14 in phase 1/2, and was the 303rd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

Part 1: This is a multi-center evaluation of pegozafermin (administered weekly or every other week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in participants with NASH and NAFLD at high risk of NASH, including a pre-defined number of participants with biopsy confirmed NASH and fibrosis stages F1-F3 to be enrolled.

Part 2: This is a multi-center, open label evaluation of pegozafermin at 27 mg administered weekly for 20 weeks in participants with biopsy-proven NASH (NAS ≥4, fibrosis stage F2 or F3).

03

Conditions studied

  • NASH

Keywords

  • NASH, NAFLD
  • Liver diseases
  • Fatty Liver
  • Metabolic diseases
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must be 21 to 75 years of age inclusive, at the time of signing the form (ICF).
  • Evidence of steatosis by Fibroscan and magnetic resonance imaging based proton density fat fraction (MRI-PDFF)
  • NASH or NAFLD at high risk for NASH as reflected by AT LEAST ONE of the following:
  • Diagnosis of NASH with fibrosis (stages F1, F2 or F3), without cirrhosis, by percutaneous liver within 24 months prior to screening
  • Central obesity WITH type 2 diabetes mellitus (T2DM)
  • Central obesity WITH either increased (ALT) and/or Fibroscan vibration-controlled transient elastography (VCTE) score ≥7 KPa.
  • Part 2 only: Biopsy-proven NASH in a liver biopsy obtained within 24 weeks of baseline with fibrosis stage F2 or F3 and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation. A small number of high risk F1 allowed.

Key Exclusion Criteria:

  • disorder or a history of any illness that, in the opinion of the Investigator, might confound the results of the study, or pose additional risk to the participant by participation in the study.
  • History of type 1 diabetes.
  • Weight loss of more than 5% within 3 months prior to Day -1 or more than 10% within 6 months prior to Day -1 or planning to try to lose weight during conduct of study.
  • History of a liver disorder other than NASH or clinical suspicion of a liver disorder other than NASH
  • History of cirrhosis or evidence of cirrhosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Part 1: Pegozafermin 3 milligrams (mg) weekly (QW)

    Participants were administered 3 mg of pegozafermin QW, via subcutaneous (SC) injection, starting on Day 1 through Day 85.

    Drug: Pegozafermin

  • Experimental
    Part 1: Pegozafermin 9 mg QW

    Participants were administered 9 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.

    Drug: Pegozafermin

  • Experimental
    Part 1: Pegozafermin 18 mg QW

    Participants were administered 18 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.

    Drug: Pegozafermin

  • Experimental
    Part 1: Pegozafermin 27 mg QW

    Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.

    Drug: Pegozafermin

  • Experimental
    Part 1: Pegozafermin 18 mg Every 2 Weeks (Q2W)

    Participants were administered 18 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.

    Drug: Pegozafermin

  • Experimental
    Part 1: Pegozafermin 36 mg Q2W

    Participants were administered 36 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.

    Drug: Pegozafermin

  • Placebo comparator
    Part 1: Placebo QW or Q2W

    Participants were administered placebo matching to pegozafermin QW or Q2W, via SC injection, starting on Day 1 through Day 85.

    Other: Placebo

  • Experimental
    Part 2: Pegozafermin 27 mg QW

    Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 134.

    Drug: Pegozafermin

Interventions

  • Subcutaneous injection

    Also known as: BIO89-100

  • OtherPlacebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Up to 113 days

  2. Part 2: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Up to 162 days

  3. Part 1: Maximum Observed Serum Concentration (Cmax) of Pegozafermin

    Time frame: Predose and up to 168 hours postdose on Day 29

  4. Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Pegozafermin

    Time frame: Predose and up to 168 hours postdose on Day 29

  5. Part 1: Time to Peak Serum Concentration (Tmax) of Pegozafermin

    Time frame: Predose and up to 168 hours postdose on Day 29

  6. Part 1: Terminal Elimination Half-life (t1/2) of Pegozafermin

    Time frame: Predose and up to 168 hours postdose on Day 29

  7. Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of Fibrosis

    NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranges from of 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH Clinical Research Network (CRN) fibrosis score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: Day 141

Secondary outcomes

  1. Part 1: Number of Participants With a Positive Anti-Drug Antibodies (ADA) Response to Pegozafermin

    Number of participants with anti-pegozafermin antibodies (ADA) with status as ADA positive has been reported.

    Time frame: Up to 113 days

  2. Parts 1 and 2: Percent Change From Baseline in Body Weight

    Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM).

    Time frame: Part 1: Baseline, Day 85; Part 2: Baseline, Day 141

  3. Parts 1 and 2: Percent Change From Baseline in Triglycerides, High Density Lipoprotein (HDL) Cholesterol (c), Non-HDLc, LDLc, Hemoglobin (HbA1C), Alanine Transaminase, Aspartate Aminotransferase, N-terminal Propeptide of Type III Collagen (Pro-C3)

    LS Mean was calculated using MMRM.

    Time frame: Part 1: Baseline, Day 92; Part 2: Baseline, Day 141

  4. Part 1: Percent Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Day 92

    LS Mean was calculated using MMRM. HOMA-IR value was calculated by multiplying fasting Glucose (mg/dL) with fasting Insulin (uIU/ml) and then dividing by 405.

    Time frame: Baseline, Day 92

  5. Part 1: Percent Change From Baseline in Adiponectin at Day 92

    LS Mean was calculated using MMRM.

    Time frame: Baseline, Day 92

  6. Part 1: Percent Change From Baseline in Free Fatty Acid at Day 92

    LS Mean was calculated using MMRM.

    Time frame: Baseline, Day 92

  7. Part 1: Percent Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR) at Day 50

    LS Mean was calculated using MMRM. Adipo-IR was derived from fasting insulin and free fatty acid.

    Time frame: Baseline, Day 50

  8. Parts 1 and 2: Percent Change From Baseline in Liver Fat as Assessed Via Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

    LS Mean was calculated using MMRM.

    Time frame: Part 1: Baseline, Day 92; Part 2: Baseline, Day 141

  9. Part 2: Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of NASH

    Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. Worsening of NASH was defined as increase ≥1 point in NAS for ballooning or inflammation. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: Day 141

  10. Part 2: Number of Participants With NASH Resolution Without Worsening of Fibrosis

    Resolution of NASH included the total absence of ballooning (score=0) and absent or mild inflammation (score 0 to 1). Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

    Time frame: Day 141

07

Results

Posted Apr 2, 2024

Participant flow

Participant flow — Overall Study
MilestonePart 1: Pegozafermin 3 Milligrams (mg) Weekly (QW)Part 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Every 2 Weeks (Q2W)Part 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QW
Started61211101491920
Received 1 dose of study drug61211101491920
Safety analysis set71211101491820
Completed5111071381819
Not completed11131111
Withdrew: Withdrawal by subject11120011
Withdrew: Adverse event00011000
Withdrew: Protocol violation00000100

Outcome measures

PrimaryPart 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Up to 113 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)
ParticipantsPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2W
Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)6477888
PrimaryPart 2: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Up to 162 days
Reported as:
Count of participants · Participants
Part 2: Number of Participants With TEAEs
ParticipantsPart 2: Pegozafermin 27 mg QW
Part 2: Number of Participants With TEAEs18
PrimaryPart 1: Maximum Observed Serum Concentration (Cmax) of Pegozafermin
Time frame:
Predose and up to 168 hours postdose on Day 29
Reported as:
Median · ng/mL
Part 1: Maximum Observed Serum Concentration (Cmax) of Pegozafermin
ng/mLPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2W
Part 1: Maximum Observed Serum Concentration (Cmax) of Pegozafermin103 (59 to 156)439 (238 to 852)901 (200 to 1281)1166 (566 to 2243)649 (160 to 1300)1674 (1300 to 2791)
PrimaryPart 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Pegozafermin
Time frame:
Predose and up to 168 hours postdose on Day 29
Reported as:
Median · ng*hour/mL
Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Pegozafermin
ng*hour/mLPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2W
Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Pegozafermin11879 (7350 to 17778)42576 (24394 to 70300)95765 (24822 to 138904)112632 (57880 to 231937)78761 (20520 to 155994)209436 (153404 to 287414)
PrimaryPart 1: Time to Peak Serum Concentration (Tmax) of Pegozafermin
Time frame:
Predose and up to 168 hours postdose on Day 29
Reported as:
Median · hr
Part 1: Time to Peak Serum Concentration (Tmax) of Pegozafermin
hrPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2W
Part 1: Time to Peak Serum Concentration (Tmax) of Pegozafermin59.5 (47.3 to 72.0)48.0 (18.6 to 58.8)48.0 (34.7 to 72.1)48.1 (46.3 to 63.4)72.0 (47.5 to 95.2)48.0 (45.2 to 71.6)
PrimaryPart 1: Terminal Elimination Half-life (t1/2) of Pegozafermin
Time frame:
Predose and up to 168 hours postdose on Day 29
Reported as:
Median · hr
Part 1: Terminal Elimination Half-life (t1/2) of Pegozafermin
hrPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2W
Part 1: Terminal Elimination Half-life (t1/2) of Pegozafermin57.1 (54.0 to 75.3)46.3 (36.1 to 67.7)68.1 (50.8 to 114.0)53.0 (27.9 to 62.2)54.4 (45.5 to 70.4)53.2 (37.4 to 62.2)
PrimaryPart 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of Fibrosis

NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranges from of 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH Clinical Research Network (CRN) fibrosis score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
Day 141
Reported as:
Count of participants · Participants
Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of Fibrosis
ParticipantsPart 2: Pegozafermin 27 mg QW
Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of Fibrosis12
SecondaryPart 1: Number of Participants With a Positive Anti-Drug Antibodies (ADA) Response to Pegozafermin

Number of participants with anti-pegozafermin antibodies (ADA) with status as ADA positive has been reported.

Time frame:
Up to 113 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With a Positive Anti-Drug Antibodies (ADA) Response to Pegozafermin
ParticipantsPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2W
Part 1: Number of Participants With a Positive Anti-Drug Antibodies (ADA) Response to Pegozafermin19771162
SecondaryParts 1 and 2: Percent Change From Baseline in Body Weight

Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM).

Time frame:
Part 1: Baseline, Day 85; Part 2: Baseline, Day 141
Reported as:
Least squares mean · Percent change
Parts 1 and 2: Percent Change From Baseline in Body Weight
Percent changePart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QW
Parts 1 and 2: Percent Change From Baseline in Body Weight1.19 ± 1.062.59 ± 0.742.47 ± 0.79-0.80 ± 0.862.11 ± 0.692.64 ± 0.861.38 ± 0.59-3.10 ± 0.83
SecondaryParts 1 and 2: Percent Change From Baseline in Triglycerides, High Density Lipoprotein (HDL) Cholesterol (c), Non-HDLc, LDLc, Hemoglobin (HbA1C), Alanine Transaminase, Aspartate Aminotransferase, N-terminal Propeptide of Type III Collagen (Pro-C3)

LS Mean was calculated using MMRM.

Time frame:
Part 1: Baseline, Day 92; Part 2: Baseline, Day 141
Reported as:
Least squares mean · Percent change
Parts 1 and 2: Percent Change From Baseline in Triglycerides, High Density Lipoprotein (HDL) Cholesterol (c), Non-HDLc, LDLc, Hemoglobin (HbA1C), Alanine Transaminase, Aspartate Aminotransferase, N-terminal Propeptide of Type III Collagen (Pro-C3)
Percent changePart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QW
Triglycerides-22.74 ± 11.53-23.95 ± 7.74-17.71 ± 8.20-27.63 ± 9.66-28.49 ± 8.62-20.71 ± 9.74-2.21 ± 6.23-25.30 ± 5.66
HDLc18.17 ± 5.4311.19 ± 3.689.20 ± 3.922.90 ± 4.5020.10 ± 3.739.79 ± 4.561.96 ± 2.9722.65 ± 5.58
Non HDLc-6.31 ± 6.45-13.87 ± 4.61-1.92 ± 4.74-16.32 ± 5.51-7.75 ± 4.38-6.34 ± 5.391.18 ± 3.56-17.12 ± 3.53
LDLc-6.17 ± 7.38-13.45 ± 5.292.59 ± 5.41-16.46 ± 6.34-5.02 ± 5.06-4.11 ± 6.201.15 ± 4.08-12.36 ± 4.80
HbA1C7.36 ± 4.051.80 ± 2.843.05 ± 2.99-3.66 ± 3.42-1.85 ± 2.606.89 ± 3.430.61 ± 2.28-7.23 ± 1.66
Alanine Transaminase-16.87 ± 10.62-26.65 ± 6.99-26.73 ± 7.40-43.69 ± 8.55-18.83 ± 6.38-39.84 ± 8.42-4.18 ± 5.47-45.80 ± 3.86
Aspartate Aminotransferase-29.36 ± 9.47-19.90 ± 6.15-15.10 ± 6.52-37.88 ± 7.52-11.41 ± 5.63-25.32 ± 7.43-4.40 ± 4.85-47.28 ± 3.54
Pro-C3-19.71 ± 14.53-18.79 ± 9.021.08 ± 9.38-27.67 ± 11.20-11.18 ± 8.19-12.76 ± 11.223.26 ± 7.02-19.52 ± 3.28
SecondaryPart 1: Percent Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Day 92

LS Mean was calculated using MMRM. HOMA-IR value was calculated by multiplying fasting Glucose (mg/dL) with fasting Insulin (uIU/ml) and then dividing by 405.

Time frame:
Baseline, Day 92
Reported as:
Least squares mean · Percent change
Part 1: Percent Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Day 92
Percent changePart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2W
Part 1: Percent Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Day 9210.37 ± 51.307.40 ± 30.6237.07 ± 20.87-41.42 ± 19.48-4.57 ± 15.57-41.11 ± 23.39-0.09 ± 15.72
SecondaryPart 1: Percent Change From Baseline in Adiponectin at Day 92

LS Mean was calculated using MMRM.

Time frame:
Baseline, Day 92
Reported as:
Least squares mean · Percent change
Part 1: Percent Change From Baseline in Adiponectin at Day 92
Percent changePart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2W
Part 1: Percent Change From Baseline in Adiponectin at Day 9237.65 ± 14.4825.46 ± 9.8829.09 ± 10.4760.85 ± 12.0023.11 ± 9.0724.14 ± 12.10-4.25 ± 7.80
SecondaryPart 1: Percent Change From Baseline in Free Fatty Acid at Day 92

LS Mean was calculated using MMRM.

Time frame:
Baseline, Day 92
Reported as:
Least squares mean · Percent change
Part 1: Percent Change From Baseline in Free Fatty Acid at Day 92
Percent changePart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2W
Part 1: Percent Change From Baseline in Free Fatty Acid at Day 9228.70 ± 24.6850.20 ± 21.0527.08 ± 17.7651.58 ± 22.0843.85 ± 18.1756.12 ± 20.8120.91 ± 13.96
SecondaryPart 1: Percent Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR) at Day 50

LS Mean was calculated using MMRM. Adipo-IR was derived from fasting insulin and free fatty acid.

Time frame:
Baseline, Day 50
Reported as:
Least squares mean · Percent change
Part 1: Percent Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR) at Day 50
Percent changePart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2W
Part 1: Percent Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR) at Day 50-6.12 ± 61.7182.00 ± 59.793.28 ± 60.0178.40 ± 46.41-25.96 ± 42.75-10.36 ± 50.33-15.82 ± 32.62
SecondaryParts 1 and 2: Percent Change From Baseline in Liver Fat as Assessed Via Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

LS Mean was calculated using MMRM.

Time frame:
Part 1: Baseline, Day 92; Part 2: Baseline, Day 141
Reported as:
Least squares mean · Percent change
Parts 1 and 2: Percent Change From Baseline in Liver Fat as Assessed Via Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
Percent changePart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QW
Parts 1 and 2: Percent Change From Baseline in Liver Fat as Assessed Via Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)-36.94 ± 11.01-49.62 ± 7.73-36.11 ± 8.14-60.39 ± 9.40-43.19 ± 6.99-50.39 ± 9.079.77 ± 6.04-64.69 ± 3.38
SecondaryPart 2: Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of NASH

Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. Worsening of NASH was defined as increase ≥1 point in NAS for ballooning or inflammation. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
Day 141
Reported as:
Count of participants · Participants
Part 2: Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of NASH
ParticipantsPart 2: Pegozafermin 27 mg QW
Part 2: Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of NASH5
SecondaryPart 2: Number of Participants With NASH Resolution Without Worsening of Fibrosis

Resolution of NASH included the total absence of ballooning (score=0) and absent or mild inflammation (score 0 to 1). Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

Time frame:
Day 141
Reported as:
Count of participants · Participants
Part 2: Number of Participants With NASH Resolution Without Worsening of Fibrosis
ParticipantsPart 2: Pegozafermin 27 mg QW
Part 2: Number of Participants With NASH Resolution Without Worsening of Fibrosis6

Adverse events

Collected over Adverse Events were collected after dosing to end of study (up to 113 days for Part 1 and up to 162 days for Part 2).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Pegozafermin 3 mg QW0/7 (0%)0/7 (0%)6/7 (85.7%)
Part 1: Pegozafermin 9 mg QW0/12 (0%)0/12 (0%)4/12 (33.3%)
Part 1: Pegozafermin 18 mg QW0/11 (0%)0/11 (0%)7/11 (63.6%)
Part 1: Pegozafermin 27 mg QW0/10 (0%)0/10 (0%)7/10 (70%)
Part 1: Pegozafermin 18 mg Q2W0/14 (0%)1/14 (7.1%)8/14 (57.1%)
Part 1: Pegozafermin 36 mg Q2W0/9 (0%)1/9 (11.1%)8/9 (88.9%)
Part 1: Placebo QW or Q2W0/18 (0%)0/18 (0%)8/18 (44.4%)
Part 2: Pegozafermin 27 mg QW0/20 (0%)0/20 (0%)18/20 (90%)
Most frequent serious events
Most frequent serious events
EventPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QW
COVID-19Infections and infestations0/70/120/110/101/141/90/180/20
Most frequent other events
Showing 10 of 72
Most frequent other events
EventPart 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QW
Increased AppetiteMetabolism and nutrition disorders4/72/120/112/102/140/90/180/20
NauseaGastrointestinal disorders1/70/121/110/103/140/93/1810/20
DiarrhoeaGastrointestinal disorders1/72/120/112/101/142/94/187/20
Upper Respiratory Tract InfectionInfections and infestations2/70/120/111/101/140/90/180/20
HeadacheNervous system disorders1/70/120/112/102/142/91/181/20
LymphadenopathyBlood and lymphatic system disorders0/70/120/112/100/140/90/180/20
Abdominal Pain UpperGastrointestinal disorders0/70/121/110/100/140/90/184/20
VomitingGastrointestinal disorders1/71/120/110/101/140/91/184/20
FatigueGeneral disorders1/70/120/110/100/140/90/184/20
Abdominal TendernessGastrointestinal disorders0/72/120/110/100/140/90/180/20

Baseline characteristics

Analysis population description: For Part 1, randomized analysis set included all randomized participants who received at least 1 dose of investigational product. For Part 2, Full analysis set included all enrolled participants who received at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(years)Part 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QWTotal
Mean56.13 ± 8.2349.50 ± 11.4551.47 ± 13.3951.96 ± 9.8351.22 ± 8.1452.46 ± 8.7352.62 ± 8.9958.44 ± 9.0752.97 ± 1.81
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QWTotal
Female5688101121565
Male1632487536
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QWTotal
Hispanic or Latino61191013916579
Not Hispanic or Latino01201031522
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Pegozafermin 3 mg QWPart 1: Pegozafermin 9 mg QWPart 1: Pegozafermin 18 mg QWPart 1: Pegozafermin 27 mg QWPart 1: Pegozafermin 18 mg Q2WPart 1: Pegozafermin 36 mg Q2WPart 1: Placebo QW or Q2WPart 2: Pegozafermin 27 mg QWTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000101
Black or African American102010105
White511910139172094
More than one race000000000
Unknown or Not Reported010000001
08

Study locations

26 sites
  • 89bio Clinical Study Site
    Madison, Alabama 35758, United States
  • 89bio Clinical Study Site
    Chandler, Arizona 85224, United States
  • 89bio Clinical Study Site
    Tucson, Arizona 85712, United States
  • 89bio Clinical Study Site
    Chula Vista, California 91911, United States
  • 89bio Clinical Study Site
    Huntington Beach, California 92647, United States
  • 89bio Clinical Study Site
    Montclair, California 91763, United States
  • 89bio Clinical Study Site
    Miami Lakes, Florida 33014, United States
  • 89bio Clinical Study Site
    Miami, Florida 33014-3616, United States
  • 89bio Clinical Study Site
    Ocala, Florida 34471, United States
  • 89bio Clinical Study Site
    Sarasota, Florida 34240, United States
  • 89bio Clinical Study Site
    Lake Charles, Louisiana 70601, United States
  • 89bio Clinical Study Site
    Berlin, New Jersey 08009, United States
  • 89bio Clinical Study Site
    Florham Park, New Jersey 07932, United States
  • 89bio Clinical Study Site
    East Syracuse, New York 13057, United States
  • 89bio Clinical Study Site
    Concord, North Carolina 28027, United States
  • 89bio Clinical Study Site
    Raleigh, North Carolina 27612, United States
  • 89bio Clinical Study Site
    Greenwood, South Carolina 29646, United States
  • 89bio Clinical Study Site
    Summerville, South Carolina 29485, United States
  • 89bio Clinical Study Site
    Hermitage, Tennessee 37076, United States
  • 89bio Clinical Study Site
    Austin, Texas 78757, United States
  • 89bio Clinical Study Site
    Edinburg, Texas 78539, United States
  • 89bio Clinical Study Site
    Houston, Texas 77058, United States
  • 89bio Clinical Study Site
    San Antonio, Texas 78215, United States
  • 89bio Clinical Study Site
    San Antonio, Texas 78229, United States
  • 89bio Clinical Study Site
    Wichita Falls, Texas 76301, United States
  • 89bio Clinical Study Site
    San Juan, 00927, Puerto Rico
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Aug 2020, 12 months.

Results were first posted in Apr 2024, 3 years 7 months after primary completion.

Of 21 phase 1/2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2019
First posted
Aug 7, 2019
StartActual
Jul 29, 2019
Primary completionActual
Aug 28, 2020
CompletionActual
Jan 19, 2022
Results first posted
Apr 2, 2024
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04048135
Lead sponsor
89bio, Inc.
Collaborators
ProSciento, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2019
Start date
Jul 29, 2019
Primary completion
Aug 28, 2020
Completion
Jan 19, 2022
Results posted
Apr 2, 2024
Last update
Apr 2, 2024

Study contacts

Charlton, MD
study director · 89bio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegozafermin

Start the discussion